Patients who switched from Novo Nordisk's weight-loss injections to its once-daily pill continued losing weight, according to new data presented by the Danish drugmaker Wednesday at a diabetes conference in Milan. The results could help Novo Nordisk defend a rare pocket of momentum as it battles Eli Lilly.